Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares

It serves biotechnology and pharmaceutical companies, as well as healthcare providers targeting patients with genetic, oncological, and autoimmune conditions.Does the transaction reflect a change in selling cadence or capacity constraints? The sale is in line with the recent median for Leonard’s open-market activity, suggesting the cadence has not materially changed and that trade sizes have not been reduced due to shrinking available share capacity.Was the sale executed from direct or indirect holdings, an ...